PD 81723 | CAS# 132861-87-1 | Adenosine binding enhancer | A1AR PAM

MedKoo Cat#: 414815 | Name: PD 81723

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PD 81723 is an Adenosine binding enhancer. PD-81723 is an A1AR PAM. PD-81723 induced sphingosine kinase (SK)1 mRNA and protein expression in HK-2 cells and in the mouse kidney.

Chemical Structure

PD 81723

CAS#132861-87-1

Theoretical Analysis

MedKoo Cat#: 414815

Name: PD 81723

CAS#: 132861-87-1

Chemical Formula: C14H12F3NOS

Exact Mass: 299.0592

Molecular Weight: 299.31

Elemental Analysis: C, 56.18; H, 4.04; F, 19.04; N, 4.68; O, 5.35; S, 10.71

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 525.00	2 Weeks
50mg	USD 1,150.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

PD 81723; PD81723; PD-81723; PD81,723; PD 81,723; PD-81,723

IUPAC/Chemical Name

Methanone, (2-amino-4,5-dimethyl-3-thienyl)(3-(trifluoromethyl)phenyl)-

InChi Key

KKDKAWKYGCUOGR-UHFFFAOYSA-N

InChi Code

InChI=1S/C14H12F3NOS/c1-7-8(2)20-13(18)11(7)12(19)9-4-3-5-10(6-9)14(15,16)17/h3-6H,18H2,1-2H3

SMILES Code

O=C(C1=C(N)SC(C)=C1C)C2=CC=CC(C(F)(F)F)=C2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 299.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Vincenzi F, Targa M, Romagnoli R, Merighi S, Gessi S, Baraldi PG, Borea PA, Varani K. TRR469, a potent A(1) adenosine receptor allosteric modulator, exhibits anti-nociceptive properties in acute and neuropathic pain models in mice. Neuropharmacology. 2014 Jun;81:6-14. doi: 10.1016/j.neuropharm.2014.01.028. Epub 2014 Jan 31. PMID: 24486382. 2: Park SW, Kim JY, Ham A, Brown KM, Kim M, D'Agati VD, Lee HT. A1 adenosine receptor allosteric enhancer PD-81723 protects against renal ischemia- reperfusion injury. Am J Physiol Renal Physiol. 2012 Sep;303(5):F721-32. doi: 10.1152/ajprenal.00157.2012. Epub 2012 Jul 3. PMID: 22759398; PMCID: PMC3468496. 3: Peeters MC, Wisse LE, Dinaj A, Vroling B, Vriend G, Ijzerman AP. The role of the second and third extracellular loops of the adenosine A1 receptor in activation and allosteric modulation. Biochem Pharmacol. 2012 Jul 1;84(1):76-87. doi: 10.1016/j.bcp.2012.03.008. Epub 2012 Mar 23. PMID: 22449615. 4: Pietra D, Borghini A, Breschi MC, Bianucci AM. Enhancer and competitive allosteric modulation model for G-protein-coupled receptors. J Theor Biol. 2010 Dec 21;267(4):663-75. doi: 10.1016/j.jtbi.2010.08.024. Epub 2010 Aug 26. PMID: 20800599. 5: Narlawar R, Lane JR, Doddareddy M, Lin J, Brussee J, Ijzerman AP. Hybrid ortho/allosteric ligands for the adenosine A(1) receptor. J Med Chem. 2010 Apr 22;53(8):3028-37. doi: 10.1021/jm901252a. PMID: 20345101. 6: Romagnoli R, Baraldi PG, Moorman AR, Iaconinoto MA, Carrion MD, Cara CL, Tabrizi MA, Preti D, Fruttarolo F, Baker SP, Varani K, Borea PA. Microwave- assisted synthesis of thieno[2,3-c]pyridine derivatives as a new series of allosteric enhancers at the adenosine A(1) receptor. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5530-3. doi: 10.1016/j.bmcl.2006.08.041. Epub 2006 Aug 22. PMID: 16931014. 7: Bhattacharya S, Youkey RL, Ghartey K, Leonard M, Linden J, Tucker AL. The allosteric enhancer PD81,723 increases chimaeric A1/A2A adenosine receptor coupling with Gs. Biochem J. 2006 May 15;396(1):139-46. doi: 10.1042/BJ20051422. PMID: 16390330; PMCID: PMC1449996. 8: Klaasse EC, van den Hout G, Roerink SF, de Grip WJ, Ijzerman AP, Beukers MW. Allosteric modulators affect the internalization of human adenosine A1 receptors. Eur J Pharmacol. 2005 Oct 17;522(1-3):1-8. doi: 10.1016/j.ejphar.2005.08.052. Epub 2005 Oct 7. PMID: 16214128. 9: Shen J, Halenda SP, Sturek M, Wilden PA. Novel mitogenic effect of adenosine on coronary artery smooth muscle cells: role for the A1 adenosine receptor. Circ Res. 2005 May 13;96(9):982-90. doi: 10.1161/01.RES.0000165800.81876.52. Epub 2005 Apr 14. PMID: 15831818. 10: de Ligt RA, Rivkees SA, Lorenzen A, Leurs R, IJzerman AP. A "locked-on," constitutively active mutant of the adenosine A1 receptor. Eur J Pharmacol. 2005 Mar 7;510(1-2):1-8. doi: 10.1016/j.ejphar.2005.01.007. PMID: 15740718. 11: Klaasse E, de Ligt RA, Roerink SF, Lorenzen A, Milligan G, Leurs R, IJzerman AP. Allosteric modulation and constitutive activity of fusion proteins between the adenosine A1 receptor and different 351Cys-mutated Gi alpha-subunits. Eur J Pharmacol. 2004 Sep 19;499(1-2):91-8. doi: 10.1016/j.ejphar.2004.07.108. PMID: 15363955. 12: Joshi E, Chordia MD, Macdonald TL, Linden J, Olsson R. Regioselective oxidation of 2-amino-3-aroyl-4,5-dialkylthiophenes by DMSO. Bioorg Med Chem Lett. 2004 Feb 23;14(4):929-33. doi: 10.1016/j.bmcl.2003.12.010. PMID: 15012996. 13: Meno JR, Higashi H, Cambray AJ, Zhou J, D'Ambrosio R, Winn HR. Hippocampal injury and neurobehavioral deficits are improved by PD 81,723 following hyperglycemic cerebral ischemia. Exp Neurol. 2003 Sep;183(1):188-96. doi: 10.1016/s0014-4886(03)00162-6. PMID: 12957503. 14: Bueters TJ, van Helden HP, Danhof M, IJzerman AP. Effects of the adenosine A1 receptor allosteric modulators PD 81,723 and LUF 5484 on the striatal acetylcholine release. Eur J Pharmacol. 2002 Nov 15;454(2-3):177-82. doi: 10.1016/s0014-2999(02)02494-9. PMID: 12421644. 15: Martynyuk AE, Zima A, Seubert CN, Morey TE, Belardinelli L, Dennis DM. Potentiation of the negative dromotropic effect of adenosine by rapid heart rates: possible ionic mechanism. Basic Res Cardiol. 2002 Jul;97(4):295-304. doi: 10.1007/s00395-002-0354-y. PMID: 12111039. 16: Kourounakis A, Visser C, de Groote M, IJzerman AP. Differential effects of the allosteric enhancer (2-amino-4,5-dimethyl-trienyl)[3-trifluoromethyl) phenyl]methanone (PD81,723) on agonist and antagonist binding and function at the human wild-type and a mutant (T277A) adenosine A1 receptor. Biochem Pharmacol. 2001 Jan 15;61(2):137-44. doi: 10.1016/s0006-2952(00)00536-0. PMID: 11163328. 17: Baraldi PG, Zaid AN, Lampronti I, Fruttarolo F, Pavani MG, Tabrizi MA, Shryock JC, Leung E, Romagnoli R. Synthesis and biological effects of a new series of 2-amino-3-benzoylthiophenes as allosteric enhancers of A1-adenosine receptor. Bioorg Med Chem Lett. 2000 Sep 4;10(17):1953-7. doi: 10.1016/s0960-894x(00)00379-6. PMID: 10987425. 18: Jarvis MF, Gessner G, Shapiro G, Merkel L, Myers M, Cox BF, Martin GE. Differential effects of the adenosine A(1) receptor allosteric enhancer PD 81,723 on agonist binding to brain and adipocyte membranes. Brain Res. 1999 Sep 4;840(1-2):75-83. doi: 10.1016/s0006-8993(99)01747-3. PMID: 10517954. 19: van der Klein PA, Kourounakis AP, IJzerman AP. Allosteric modulation of the adenosine A(1) receptor. Synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding. J Med Chem. 1999 Sep 9;42(18):3629-35. doi: 10.1021/jm991051d. PMID: 10479294. 20: Schreieck J, Richardt G. Endogenous adenosine reduces the occurrence of ischemia-induced ventricular fibrillation in rat heart. J Mol Cell Cardiol. 1999 Jan;31(1):123-34. doi: 10.1006/jmcc.1998.0858. PMID: 10072721.